Q3 guidance implies flat to small sequential growth compared to robust Q2 growth. Is this due to seasonality or manufacturing issues?

The conservative Q3 outlook is due to several very large orders that are close to the end of the third quarter and were considered at risk of not closing within the quarter. “It's actually caused by several very large orders that are very close to the end of the third quarter and we thought they were at risk. So we were conservative in our outlook towards whether we would close them this quarter or next quarter.”

Is the current growth primarily driven by increased utilization from existing clients or new client acquisition?

The majority of the growth is coming from existing clients, particularly strong demand from clinical users, and this trend is expected to continue in coming quarters. “The majority of our growth is coming from existing clients. It's very strong demand with especially our clinical users.”

Has the new CPT code pricing for hematology started to drive consumable sales or revenue?

Management believes the new CPT code pricing is starting to drive sales in the US, and a similar trend is observed in Europe with gaining coverage. “That's a great question, and right now we think it is starting to drive the sales. And only time will tell if that's factual or not. But we believe it's true here in the States.”

BNGO

Bionano (BNGO) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 10, 2026

Source: earnings call transcript

Executive summary

Bionano Q2 FY26 — Strong Consumable Growth Driven by Clinical Adoption

Bionano reported strong Q2 FY26 results, primarily driven by increased clinical adoption and utilization of its Optical Genome Mapping (OGM) platform, particularly in international markets. The company achieved its highest-ever gross margin and simplified its financial profile by fully retiring its convertible debt. While flow cell demand outpaces supply, Bionano remains focused on driving profitable growth with existing users and expanding OGM's clinical evidence base.

Highlights

Consumable revenue increased 30% year-over-year to $4.3 million.
Flow cells sold were up 27% year-over-year to a record 9,219 units.
Adjusted gross margin reached 53% in Q2 2026, the highest quarterly margin to date.
Total revenue grew 21% year-over-year to $8.2 million, exceeding guidance.
The company fully retired its outstanding senior secured convertible debt.

Concerns

Software revenue decreased 16% year-over-year to $1.4 million due to timing delays in customer deployments.
Demand for flow cells continues to outpace current manufacturing capacity, resulting in a backlog.
Q3 revenue guidance of $8.2 million to $8.6 million implies flat to small sequential growth, attributed to large orders at risk near quarter-end.

Guidance & targets

Category	Target	Timeline	Confidence
Full-year 2026 Revenue	$31M-$33M high materiality	FY26	High
Q3 2026 Revenue	$8.2M-$8.6M medium materiality	Q3 · FY26	High
Cash Runway	into at least Q1 2027 high materiality	Q1 · FY27	High
Ionic OGM Expansion Launch	launch in Q4 2026 medium materiality	Q4 · FY26	High
Flow Cell Manufacturing Capacity	remedy by the end or at least the middle to the end of the fourth quarter coming up high materiality	Q4 · FY26	Medium

Segment performance

Segment	Revenue	YoY	QoQ	Margin
Consumables Growth primarily from an increase in flow cells sold, consistent with clinical adoption.	$4.3M	30%	—	—
Software Reflects timing delays in deployment from certain customers.	$1.4M	-16%	—	—
Other (Instruments and Services) Led by higher instrument sales as new customers came onto the platform.	$2.5M	38%	—	—

Product announcements

Product	Type	Timeline	Details
Ionic OGM expansion	launch	Q4 2026

Risks & headwinds

Flow cell manufacturing capacity constraints Current, expected to be remedied by mid-to-end Q4 2026

Demand continues to outpace supply, leading to backlog.

Mitigation:Working to increase manufacturing capacity; hope to remedy by mid-to-end Q4.

Software revenue decline Q2 FY26

Down 16% year-over-year to $1.4 million.

Mitigation:Attributed to timing delays in deployment from certain customers; no specific mitigation stated beyond addressing deployment timing.

Conservative Q3 revenue outlook Q3 FY26

Q3 guidance of $8.2M-$8.6M implies flat to small sequential growth.

Mitigation:Due to several very large orders close to quarter-end being at risk; management was conservative in their outlook.

What to watch in Q3 FY26

Flow cell manufacturing capacity

Q4 FY26

Current Demand outpaces supply, backlog exists

Target Backlog reduced, supply meets demand

Why it matters

Resolving supply constraints is critical for meeting demand and achieving revenue targets, especially given the raised low-end guidance.

We're very much constrained in terms of our flow cell manufacturing capacity, and as we mentioned in the call earlier, we are in back order and hope to remedy that by the end or at least the middle to the end of the fourth quarter coming up.

Find out whether BNGO delivers this. Inve re-checks your case every morning.

Q&A highlights

Why was only the low end of the full-year revenue guidance raised, not the high end?

Management stated that flow cell manufacturing capacity is constrained, leading to a backlog. They are reluctant to raise the top line until manufacturing can consistently meet demand, which they hope to remedy by mid-to-end Q4.

“We're reluctant to raise the top line until we know for certain that our manufacturing can keep up with demand.”

asked by Yi Chen · answered by Albert Luderer

2 min read 5 chapters

Detailed narrative

Strategic Refocus on Profitable Growth

Since September 2024, Bionano has deliberately shifted its strategy from aggressive installed base expansion to driving profitable growth with existing routine users. This involves selective new customer acquisition, prioritizing high-volume prospects, and focusing on four strategic pillars: supporting the installed base, increasing OGM utilization, building reimbursement support, and improving profitability and scalability through lower costs and higher volumes.

Accelerated Clinical Adoption and Utilization

The company reported a record 9,219 flow cells sold in Q2 2026, a 27% year-over-year increase, primarily driven by increased clinical adoption and utilization from existing customers. This trend is evident in consumable revenue growing 30% year-over-year to $4.3 million. The shift towards a higher proportion of recurring consumable-led revenue indicates a healthier and more predictable business mix, directly aligning with the company's strategic goals.

Expanding Reimbursement and Clinical Evidence Base

The two Category I CPT codes for OGM in hematologic malignancies ($1,853.22) and constitutional genetic disorders ($1,263.53) are now translating into real clinical adoption and utilization. Momentum in evidence generation continues, with a landmark T-ALL study demonstrating OGM's superior detection of genomic abnormalities (97.8% vs. 55% by karyotyping) and multiple studies expanding OGM's utility in reproductive health and prenatal genetic disorders.

Improved Profitability and Financial Health

Bionano achieved its highest quarterly adjusted gross margin to date at 53% in Q2 2026, up from high-20% in 2023, reflecting continued operational efficiencies. The company also fully retired its outstanding senior secured convertible debt, simplifying its financial profile. These efforts are expected to drive the company towards adjusted EBITDA breakeven and sustainable profitability, with a cash runway extending into at least Q1 2027.

Product Development and International Market Expansion

Bionano continues to develop its Ionic system, with an OGM expansion targeted for launch in Q4 2026, expected to contribute to incremental consumables revenue. International markets are a key growth driver, now representing the majority of total revenue, attributed to broadening clinical adoption at leading European institutions. The company also welcomed back Dr. Alex Hastie as Chief Scientific Officer, reinforcing its commitment to scientific leadership.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.